Latest Breaking News On - Stefan fraenkel - Page 1 : comparemela.com

Vesey Street Capital Partners Announces Majority Recapitalization of Inceptua Group

/PRNewswire/ Vesey Street Capital Partners, LLC ("VSCP"), a New York-based healthcare services private equity firm, announced that funds managed by VSCP.

United statesNew yorkAdam feinsteinDoug cookTiffany viscontiPeter krantzStefan fraenkelAnimal health at cencora incInceptua groupGrant thorntonAmerisourcebergen corporationGlobal commercialization servicesCompany asCapital partnersStreet capital partnersNew york based

Inceptua receives approval of marketing authorization transfer of Apealea® (paclitaxel micellar) for the treat

European Commission and MHRA approves transfer of marketing authorization from Oasmia Pharmaceutical AB to Inceptua AB

United kingdomInceptua pharmaNicole anscombe coxClive whitcherStefan fraenkelElevar therapeutics incDear editorial teamEuropean commissionInceptua groupRegulatory agencyEditorial teamUnited kingdom medicinesOasmia pharmaceuticalLife science newswireChief executive officerElevar therapeutics

Apt Diffamation présumée : la cour d appel statue en faveur de l ancien candidat LREM Thévenieau

Apt Diffamation présumée : la cour d appel statue en faveur de l ancien candidat LREM Thévenieau
ledauphine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ledauphine.com Daily Mail and Mail on Sunday newspapers.

Sara brofmannStefan fraenkelDangerous dominicaCivil procedureசிவில் ப்ரொஸீஜர்

Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

Share: SALT LAKE CITY, Dec. 28, 2020 /PRNewswire/ Elevar Therapeutics, Inc. ( Elevar ), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it has entered into an exclusive agreement with Inceptua Group ( Inceptua ) for the distribution and commercialization of Apealea® (paclitaxel micellar) in Europe. Apealea has been authorized by European regulatory authorities for use in the European Economic Area in combination with carboplatin for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

United statesSouth koreaLindsay roccoInceptua pharmaAlex kimStefan fraenkelHistochem cytochemInceptua groupEuropean commissionDrug administrationElevar therapeutics incInceptua servicesElixir health public relationsAmerican cancer society about ovarianElevar therapeuticsEuropean economic area